Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528666 · ClinicalTrials.gov registry record
Risk Perception in Multiple Sclerosis
A clinical trial of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,361
- Enrollment target
- 1
- Study location
NCT05528666: Completed study of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT05528666 is a study of Multiple Sclerosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,361 participants, above the 571-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (664% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05528666, a study of Multiple Sclerosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,361 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
Primary Outcome
Proportion of patients who were switched based on risk perception (infections, malignancies, others) were reported.
Conditions Studied
Interventions
- OTHER High Efficacy Therapy (HET)
- OTHER Non High Efficacy Therapy (Non-HET)
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,361 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2021-09-17 |
What the finished NCT05528666 record still lists
NCT05528666 is an observational study that tracks outcomes without assigning an intervention. Its 4,361 participants enrollment target places it among the larger protocols in the corpus, above the 571-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (664% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which High Efficacy Therapy (HET) is the first listed.
NCT05528666 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05528666 about?
NCT05528666 is a clinical study titled "Risk Perception in Multiple Sclerosis". This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and ...
What is the current status of trial NCT05528666?
This trial is currently completed. The enrollment target is 4,361 participants. The study started on 2021-09-09. Estimated completion is 2021-09-17.
What conditions does trial NCT05528666 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05528666?
The interventions under investigation include: High Efficacy Therapy (HET) (OTHER), Non High Efficacy Therapy (Non-HET) (OTHER).
Who is sponsoring clinical trial NCT05528666?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05528666 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05528666's enrollment target sits among peer trials
4,361 8th of 315 higher than 308 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI